CTLA4 and neoplasm: Combining peptide vaccines with immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies, has shown promising results by counteracting the immunosuppressive tumor microenvironment [18].